SITUATION ANALYSIS and RECOMMENDATIONS Antibiotic Use and Resistance in Tanzania
Total Page:16
File Type:pdf, Size:1020Kb
SITUATION ANALYSIS AND RECOMMENDATIONS Antibiotic Use and Resistance in Tanzania The GARP-Tanzania Working Group Said Aboud, MD, PhD, Chairman Robinson Mdegela, BVSc, PhD, Vice-chairman June 2015 1 GARP TANZANIA WORKING GROUP Said Aboud, MD, PhD, Chairman, Associate Professor of Microbiology and Immunology, Muhimbili University of Health and Allied Sciences (MUHAS) Robinson Mdegela, BVSc, PhD, Vice-chairman, Professor of Veterinary Medicine, Sokoine University of Agriculture (SUA) Pastory Dulla, DVM, PGD PM, Vice chairman, Veterinary Council of Tanzania, Chairman Veterinary Pharmaceutical Committee, Ministry of Fisheries and Livestock Development Abdu Hayghaimo, BVSc, MVM, Director of Veterinary Services, Ministry of Livestock and Fisheries Development Dominick Kambarage, BVSc, PhD, Professor of Veterinary Medicine and Vice Chancellor, Julius Nyerere University of Agriculture Rudovick Kazwala, BVSc, PhD, Professor of Veterinary Medicine and Public Health, SUA Jaffary Liana, B.Pharm, Senior technical advisor and local project lead for the Sustainable Drug Seller Initiative (SDSI) program, MSH Siana Mapunjo, B.Pharm, Principal Pharmacist, Ministry of Health and Social Welfare Mary Masanja, B.Pharm, M.Ed, Drug registration, Tanzania Food and Drugs Authority (TFDA) Doreen Mloka, MSc, PhD, Lecturer, Pharmaceutical Microbiology, MUHAS Fausta Mosha, MD, PhD, Director, National Health Laboratory Quality Assurance and Training Centre (NHLQATC) Stephen Mshana, MD, PhD, Associate Professor of Microbiology and Immunology, Catholic University of Health and Allied Sciences Hamisi Nikuli, Cert. Animal Health and Production, MVSc, Coordinator Aquatic Animal and Public Health, Ministry of Livestock and Fisheries Development Balthazar Nyombi, PhD, Senior Laboratory Scientist, Kilimanjaro Christian Medical Centre (KCMC) Eva Ombaka, B.Pharm, PhD, St. John University Meshack Shimwela, MD, MMED, Medical Officer in Charge, Amana Regional Referral Hospital Richard Silumbe, B.Pharm, M.Sc. Pharmaceutical Management, PGD M&E, ADDO Program Coordinator, Pharmacy Council Longinus Tegulirwa, B.Sc, M.Sc. environmental science, Fisheries Health Specialist, Ministry of Livestock and Fisheries Development Edda Vuhahula, DDS, PhD, Senior Lecturer, Department of Pathology, MUHAS i OTHER CONTRIBUTORS Hezron Nonga, PhD, Senior Lecturer, Department of Veterinary Medicine and Public Health, SUA Abdul Katakweba, PhD, Senior Research Scientist, Pest Management Center, SUA GARP-TANZANIA STAFF Khadija Msami, MD, GARP-Tanzania country coordinator and Medical Officer, Ocean Road Cancer Institute GARP SECRETARIAT: Center for Disease Dynamics, Economics & Policy (CDDEP) Aleefia Somji, GARP- Tanzania Country Coordinator (until August 2013) Hellen Gelband, GARP Global Coordinator, Associate Director, CDDEP ACKNOWLEDGEMENTS We would like to acknowledge Dr. Eliudi Eliakimu of the Ministry of Health and Social Welfare Quality Assurance Department for the invaluable information given when consulted. Additional consultation was sought and kindly imparted by Dr. Albert Komba of JHPIEGO and Mr. Jacob Lusekelo of NHLQATC. Recommended citation: Global Antibiotic Resistance Partnership—Tanzania Working Group. 2015. Situation Analysis and Recommendations: Antibiotic Use and Resistance in Tanzania. Washington, DC and New Delhi: Center for Disease Dynamics, Economics & Policy. ii Table of Contents Page PREFACE ................................................................................................................................ IV CHAPTER 1: EXECUTIVE SUMMARY ..................................................................................1 BURDEN OF BACTERIAL INFECTIONS AND THEIR RESISTANCE RATES ..................................................2 FACTORS AFFECTING ANTIBIOTIC RESISTANCE AND REMEDIAL MEASURES ..........................................4 CURRENT ACTIVITIES WITH RELEVANCE TO ANTIBIOTIC RESISTANCE AND USE ...................................7 RECOMMENDATIONS ......................................................................................................................9 CHAPTER 2: POPULATION AND HEALTH BACKGROUND ..........................................13 HUMANS ................................................................................................................................13 POPULATION .........................................................................................................................................13 ECONOMY .................................................................................................................................................................13 HEALTH SYSTEM ..................................................................................................................................13 AVAILABILITY OF AND ACCESS TO ESSENTIAL MEDICINES ........................................................................20 GOVERNMENT POLICES AND THE REGULATORY ENVIRONMENT .................................................................25 ANIMALS ................................................................................................................................27 LIVESTOCK FARMING ............................................................................................................................27 FOOD ANIMAL CONTRIBUTION TO THE ECONOMY .....................................................................................27 VACCINATION ......................................................................................................................................36 GOVERNMENT POLICIES AND REGULATORY ENVIRONMENT .........................................................................37 CHAPTER 3: BURDEN OF DISEASE AND ANTIBIOTIC RESISTANCE IN HUMANS ................................................................................................................................43 NATIONAL BURDEN OF DISEASE ...................................................................................................... 43 BACTERIAL DISEASES IN HUMANS AND THEIR RESISTANCE RATES ...............................................................45 SURVEILLANCE FOR BACTERIAL INFECTIONS ............................................................................................71 CHAPTER 4: BURDEN OF DISEASE AND ANTIBIOTIC RESISTANCE IN FOOD ANIMALS ....................................................................................................................73 NATIONAL DISEASE BURDEN ........................................................................................................73 BACTERIAL DISEASE IN FARMED ANIMALS .............................................................................................. 73 ANIMAL DISEASE SURVEILLANCE ...................................................................................................77 RESISTANCE RATES .......................................................................................................................77 CHAPTER 5: ANTIBIOTIC USE AND SUPPLY CHAIN MANAGEMENT .......................80 HUMANS ................................................................................................................................80 ANTIBIOTIC USE IN HUMAN HEALTH .................................................................................................... 80 ANTIBIOTIC SUPPLY CHAIN ................................................................................................................... 82 ANIMALS ................................................................................................................................88 ANTIBIOTIC USE IN ANIMALS ................................................................................................................ 88 ANTIBIOTIC SUPPLY CHAIN ................................................................................................................... 90 iii Preface Antibiotics and other antimicrobial agents are invaluable life savers, particularly in resource-limited countries where infectious diseases are abundant. Both uncomplicated and severe infections are potentially curable as long as the aetiological agents are susceptible to the antimicrobial drugs. The rapid rate with which antimicrobial agents are becoming ineffective due to resistance acquired as a result of unchecked overuse and misuse threatens to undo the benefit of controlling infections. The evidence for resistant microorganisms, many times to more than a single antimicrobial agent, has been observed globally. In Tanzania, there is evidence in the form of few scattered studies conducted in different parts of the country in a multitude of settings including health care facilities, the community, domesticated animals and wild animals. The (multi-) resistant organisms observed in animals and animal products are passed on to even antibiotic naïve individuals through consumption of meat, milk and other animal products. This contributes to the steep decline towards ineffective antibiotics, a situation that can be likened to a siren that is getting progressively louder. Conversely, access to high quality, life-saving antibiotics has remained a challenge and the need to institute control to conserve the power of antibiotics must not be misconstrued as an obstacle to access. We need to reach a balance where on one hand antibiotics are optimally available versus limiting access to unwarranted use on the other hand. Several initiatives are part of an international response to the global health threat of AMR,